Share on StockTwits

Eli Lilly and (NYSE:LLY) VP Enrique A. Conterno unloaded 5,000 shares of Eli Lilly and stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $63.60, for a total transaction of $318,000.00. Following the completion of the sale, the vice president now directly owns 82,736 shares in the company, valued at approximately $5,262,010. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Eli Lilly and (NYSE:LLY) traded up 0.44% on Wednesday, hitting $63.9625. The stock had a trading volume of 2,497,753 shares. Eli Lilly and has a 52 week low of $47.53 and a 52 week high of $65.70. The stock has a 50-day moving average of $62.29 and a 200-day moving average of $60.26. The company has a market cap of $68.549 billion and a P/E ratio of 20.22.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Thursday, July 24th. The company reported $0.68 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.65 by $0.03. The company had revenue of $4.94 billion for the quarter, compared to the consensus estimate of $4.88 billion. During the same quarter in the prior year, the company posted $1.16 earnings per share. The company’s quarterly revenue was down 16.8% on a year-over-year basis. On average, analysts predict that Eli Lilly and will post $2.78 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on LLY shares. Analysts at Deutsche Bank initiated coverage on shares of Eli Lilly and in a research note on Wednesday, August 27th. They set a “buy” rating and a $71.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Eli Lilly and from $65.00 to $61.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Finally, analysts at S&P Equity Research initiated coverage on shares of Eli Lilly and in a research note on Friday, August 1st. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Buy” and an average price target of $64.33.

Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with Analyst Ratings Network's FREE daily email newsletter.